<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Writing Group, Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher M, Freedman A, Geretti AM, Gilleece Y, Horne R, Johnson M, Khoo S, Leen C, Marshall N, Nelson M, Orkin C, Paton N, Phillips A, Post F, Pozniak A, Sabin C, Trevelion R, Ustianowski A, Walsh J, Waters L, Wilkins E, Winston A, Youle M. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 2014 Jan;15(Suppl 1):1-85. [564 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24330011&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Gazzard B, on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008;9:563&amp;ndash;608.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Cardiovascular disease, unspecified  (429.2); End stage renal disease  (585.6); Human immunodeficiency virus [HIV] disease  (042)"/><FieldValue Value="MSH: Acquired Immunodeficiency Syndrome ; Adenine ; AIDS Dementia Complex ; Anti-HIV Agents ; Anti-Retroviral Agents ; Antiretroviral Therapy, Highly Active ; Antiviral Agents ; Cardiovascular Diseases ; Coinfection ; Deoxycytidine ; Drug Interactions ; Drug Monitoring ; Hepatitis, Viral, Human ; HIV Infections ; HIV Integrase Inhibitors ; Integrase Inhibitors ; Kidney Failure, Chronic ; Medication Adherence ; Medication Therapy Management ; Organophosphonates ; Patient Participation ; Protease Inhibitors ; Reverse Transcriptase Inhibitors ; Ritonavir ; Tuberculosis ; Women's Health Services "/><FieldValue Value="MTH: Acquired Immunodeficiency Syndrome ; Adenine ; Adherence To Medication Regime ; Antiretroviral therapy ; Antiviral Agents ; Cardiovascular Diseases ; Coinfection ; Deoxycytidine ; Drug Interactions ; emtricitabine ; HIV Infections ; HIV Integrase Inhibitors ; Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] ; Integrase Inhibitors ; Kidney Failure, Chronic ; Non-nucleoside reverse transcriptase inhibitors ; Protease Inhibitors ; Reverse Transcriptase Inhibitors ; Ritonavir ; Tenofovir ; Tuberculosis "/><FieldValue Value="PDQ: AIDS-related malignancies ; deoxycytidine ; ritonavir "/><FieldValue Value="SNOMEDCT_US: Adenine  (70203000); AIDS  (62479008); Antiviral agent  (32249005); Antiviral agent  (372701006); Client participation  (225330006); Dementia associated with AIDS  (421529006); Disorder of cardiovascular system  (49601007); Drug interaction  (404204005); Drug interaction  (79899007); Emtricitabine  (404855005); Emtricitabine  (404856006); End stage renal disease  (46177005); End stage renal disease  (90688005); Highly active anti-retroviral therapy  (416234007); Human immunodeficiency virus infection  (86406008); Integrase inhibitor  (427965001); Integrase inhibitor  (428617003); Medication compliance  (182884001); Medication compliance  (418633004); Medication monitoring  (395170001); Mixed infectious disease  (4559000); Peptide hydrolase inhibitor  (412127001); Peptide hydrolase inhibitor  (422745008); Reverse transcriptase inhibitor  (108709006); Reverse transcriptase inhibitor  (372531002); Ritonavir  (108693005); Ritonavir  (386896009); Tenofovir  (395264002); Tenofovir  (422091007); Tuberculosis  (371569005); Tuberculosis  (373576009); Tuberculosis  (56717001); Women's health service  (2651000175101)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Human immunodeficiency virus (HIV) infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acquired immune deficiency syndrome (AIDS) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Family Practice" /><FieldValue Value="Hematology" /><FieldValue Value="Infectious Diseases" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nephrology" /><FieldValue Value="Obstetrics and Gynecology" /><FieldValue Value="Oncology" /><FieldValue Value="Pharmacology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Nurses" /><FieldValue Value="Pharmacists" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Psychologists/Non-physician Behavioral Health Clinicians" /><FieldValue Value="Public Health Departments" /><FieldValue Value="Social Workers" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To provide guidance on best clinical practice in the treatment and management of adults with human immunodeficiency virus (HIV) infection with antiretroviral therapy (ART) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To provide guidance on the initiation of ART in those previously na&amp;iuml;ve to therapy, support of patients on treatment, management of patients experiencing virological failure, and recommendations in specific patient populations where other factors need to be taken into consideration &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Adults with human immunodeficiency virus (HIV) infection or acquired immune deficiency syndrome (AIDS)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xA;    &lt;li&gt;Patient involvement in decision-making &lt;/li&gt;&#xA;    &lt;li&gt;Decisions on when to start antiretroviral therapy (ART) in patients with chronic infection, patients presenting with acquired immune deficiency syndrome (AIDS) or a major infection, treatment of primary human immunodeficiency virus (HIV) infection, and treatment to reduce transmission &lt;/li&gt;&#xA;    &lt;li&gt;ART&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;        &lt;li&gt;Nucleos(t)ide reverse transcriptase inhibitor (NRTI) backbone (tenofovir [TDF] and emtricitabine [FTC] preferred) &lt;/li&gt;&#xA;        &lt;li&gt;Choice of a third agent (ritonavir-boosted protease inhibitor, non-nucleos(t)ide reverse transcriptase inhibitor [NNRTI], or an integrase inhibitor) &lt;/li&gt;&#xA;        &lt;li&gt;Novel ART strategies (recommended against) &lt;/li&gt;&#xA;    &lt;/ul&gt;&#xA;    &lt;/li&gt;&#xA;    &lt;li&gt;Supporting patients on therapy&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;        &lt;li&gt;Interventions to increase adherence to treatment &lt;/li&gt;&#xA;        &lt;li&gt;Monitoring drug interactions &lt;/li&gt;&#xA;        &lt;li&gt;Therapeutic drug monitoring &lt;/li&gt;&#xA;        &lt;li&gt;Pharmacological considerations in switching/stopping therapy &lt;/li&gt;&#xA;        &lt;li&gt;Switching ART in virological suppression &lt;/li&gt;&#xA;        &lt;li&gt;Switching antiretrovirals in combination ART &lt;/li&gt;&#xA;        &lt;li&gt;Stopping therapy (not recommended in stable patients) &lt;/li&gt;&#xA;    &lt;/ul&gt;&#xA;    &lt;/li&gt;&#xA;    &lt;li&gt;Managing virological failure &lt;/li&gt;&#xA;    &lt;li&gt;ART in specific populations (timing of treatment and choice of specific drugs)&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;        &lt;li&gt;Patients receiving tuberculosis (TB) therapy &lt;/li&gt;&#xA;        &lt;li&gt;Patients with viral hepatitis coinfection &lt;/li&gt;&#xA;        &lt;li&gt;Patients with HIV-related cancers &lt;/li&gt;&#xA;        &lt;li&gt;Patients with HIV-associated neurocognitive impairment &lt;/li&gt;&#xA;        &lt;li&gt;Patients with chronic kidney disease &lt;/li&gt;&#xA;        &lt;li&gt;Patients with cardiovascular disease &lt;/li&gt;&#xA;        &lt;li&gt;HIV-infected women &lt;/li&gt;&#xA;    &lt;/ul&gt;&#xA;    &lt;/li&gt;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Death &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;New acquired immune deficiency syndrome (AIDS) diagnosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Non-AIDS co-morbidities &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Drug adverse events, including grade 3/4 adverse events &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Drug resistance &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Human immunodeficiency virus (HIV) transmission/incidence &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Time to CD4 count &amp;lt;350 cells/&amp;mu;L &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Virological suppression &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Virological failure &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Discontinuing treatment because of adverse events &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Progressive HIV neurocognitive disorders or chronic kidney disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cardiovascular clinical events &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;For the 2012 guidelines the literature search dates were 1 January 2008 to 16 September 2011 and included MEDLINE, EMBASE and the Cochrane library. Abstracts from selected conferences (see Appendix 2 in the original guideline document [see also the Availability of Companion Documents field]) were searched between 1 January 2009 and 16 September 2011.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Systematic Literature Search&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Databases: Medline, EMBASE, Cochrane Library&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Conference abstracts:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;IAS Conference on HIV pathogenesis and treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;International AIDS conference &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Conference on Retroviruses and Opportunistic Infections &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;European Conference on Clinical Aspects and Treatment of HIV Infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Interscience Conference on Antimicrobial Agents and Chemotherapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;International Congress on Drug Therapy in HIV Infection &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;British HIV Association Annual Conference &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Date parameters:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Data bases: 2008&amp;ndash;September 2011 &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Conference abstracts: 2009&amp;ndash;September 2011 &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Limited further searches concerning specific third agents (rilpivirine [RPV] and elvitegravir [ELV]/cobicistat [COBI]) covering the period from September 2011 were carried out in 2013.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade A evidence&lt;/strong&gt; means high-quality evidence that comes from consistent results from well-performed randomized controlled trials (RCTs), or overwhelming evidence of some other sort (such as well-executed observational studies with consistent strong effects and exclusion of all potential sources of bias). Grade A implies confidence that the true effect lies close to the estimate of the effect.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade B evidence&lt;/strong&gt; means moderate-quality evidence from randomized trials that suffer from serious flaws in conduct, inconsistency, indirectness, imprecise estimates, reporting bias, or some combination of these limitations, or from other study designs with special strengths such as observational studies with consistent effects and exclusion of most potential sources of bias.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade C evidence&lt;/strong&gt; means low-quality evidence from controlled trials with several very serious limitations or observational studies with limited evidence on effects and exclusion of most potential sources of bias.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Grade D evidence&lt;/strong&gt; on the other hand is based only on case studies, expert judgement or observational studies with inconsistent effects and a potential for substantial bias, such that there is likely to be little confidence in the effect estimate.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review with Evidence Tables" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;For each topic and healthcare question, evidence was identified and evaluated by Writing Group members with expertise in the field. Using the modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) system (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field), panel members were responsible for assessing and grading the quality of evidence for predefined outcomes across studies and developing and grading the strength of recommendations. An important aspect of evaluating evidence is an understanding of the design and analysis of clinical trials, including the use of surrogate marker data.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For a number of questions, GRADE evidence profile and summary of findings tables were constructed, using predefined and rated treatment outcomes (see Appendix 3 in the original guideline document [see also the Availability of Companion Documents field]), to help achieve consensus for key recommendations and aid transparency of the process.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Guideline Development Process&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The British HIV Association (BHIVA) revised and updated the association's guideline development manual in 2011 (see the &quot;Availability of Companion Documents&quot; field). BHIVA has adopted the modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) system for the assessment, evaluation and grading of evidence and development of recommendations. Full details of the guideline development process, including conflict of interest policy, are outlined in the manual.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The scope, purpose and guideline topics were agreed by the Writing Group. Questions concerning each guideline topic were drafted and a systematic literature review undertaken by an information scientist.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The scope, purpose and guideline topics were agreed by the Writing Group. Questions concerning each guideline topic were drafted and a systematic literature review undertaken by an information scientist.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For a number of questions, GRADE evidence profile and summary of findings tables were constructed, using predefined and rated treatment outcomes (see Appendix 3 in the original guideline document [see also the Availability of Companion Documents field]), to help achieve consensus for key recommendations and aid transparency of the process.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The strength of a recommendation is determined not only by the quality of evidence for defined outcomes but also the balance between desirable and undesirable effects of a treatment or intervention, differences in values and preferences and, where appropriate, resource use. Each recommendation concerns a defined target population and is actionable.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Patient Involvement&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;BHIVA views the involvement of patient and community representatives in the guideline development process as essential. The Writing Group included two patient representatives appointed through the UK HIV Community Advisory Board (UK CAB) who were involved in all aspects of the guideline development process. In addition, two meetings with patients and community representatives were held to discuss and receive feedback and comment on the proposed guideline recommendations. The first was held before the Writing Group's consensus meeting and the second as part of the public consultation process.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Summary of the Modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) System&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1A&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Strong recommendation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;High-quality evidence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Benefits clearly outweigh risk and burdens, or vice versa. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consistent evidence from well performed randomised, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change confidence in the estimate of benefit and risk. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Strong recommendations can apply to most patients in most circumstances without reservation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinicians should follow a strong recommendation unless there is a clear rationale for an alternative approach. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1B&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Strong recommendation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Moderate-quality evidence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Benefits clearly outweigh risk and burdens, or vice versa &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evidence from randomised, controlled trials with important limitations (inconsistent results, methods flaws, indirect or imprecise), or very strong evidence of some other research design. Further research may impact on confidence in the estimate of benefit and risk. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Strong recommendation and applies to most patients. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1C&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Strong recommendation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Low-quality evidence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Benefits appear to outweigh risk and burdens, or vice versa &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evidence from observational studies, unsystematic clinical experience, or from randomised, controlled trials with serious flaws. Any estimate of effect is uncertain. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Strong recommendation, and applies to most patients. Some of the evidence base supporting the recommendation is, however, of low quality. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;1D&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Strong recommendation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Very low-quality evidence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Benefits appear to outweigh risk and burdens, or vice versa. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evidence limited to case studies. Strong recommendation based mainly on case studies and expert judgment. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2A&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Weak recommendation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;High-quality evidence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Benefits closely balanced with risks and burdens &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consistent evidence from well performed randomised, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change confidence in the estimate of benefit and risk. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Weak recommendation, best action may differ depending on circumstances or patients' or societal values. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2B&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Weak recommendation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Moderate-quality evidence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Benefits closely balanced with risks and burdens, some uncertainty in the estimates of benefits, risks and burdens. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evidence from randomised, controlled trials with important limitations (inconsistent results, methods flaws, indirect or imprecise). Further research may change the estimate of benefit and risk. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Weak recommendation, alternative approaches likely to be better for some patients under some circumstances. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2C&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Weak recommendation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Low-quality evidence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Uncertainty in the estimates of benefits, risks, and burdens; benefits may be closely balanced with risks and burdens. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evidence from observational studies, unsystematic clinical experience, or from randomised, controlled trials with serious flaws. Any estimate of effect is uncertain. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Weak recommendation; other alternatives may be reasonable. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;2D&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Weak recommendation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Very low-quality evidence. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Uncertainty in the estimates of benefits, risks, and burdens; benefits may be closely balanced with risks and burdens. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Evidence limited to case studies and expert judgment. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Very weak recommendation; other alternatives may be equally reasonable. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Good Practice Points (GPP)&lt;/strong&gt; are recommendations based on the clinical judgment and experience of the working group. GPPs emphasise an area of important clinical practice for which there is not, nor is there likely to be, any significant research evidence. They address an aspect of treatment and care that is regarded as such sound clinical practice that health care professionals are unlikely to question it and where the alternative recommendation is deemed unacceptable. It must be emphasised that GPPs are not an alternative to evidence-based recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Antiretroviral therapy (ART) is extremely cost-effective and compares favourably with the cost of management of many other chronic diseases. Estimates of the cost-effectiveness of ART have been assessed in studies in North America and Europe. Their findings have been consistent with an estimated incremental cost-effectiveness ratio of about US$20,000 per quality adjusted life year for combination ART compared with no therapy based on drug costs and treatment patterns in the USA and Europe.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The British HIV Association (BHIVA) Writing Group recognizes that cost of drugs is an important issue in the choice of ART regimens There are limited cost-effectiveness data in the UK comparing different antiretroviral (ARV) drugs and for this reason the Writing Group did not include cost-effectiveness as an outcome in ART comparisons. However, the Writing Group believes that decreasing the risk of virological failure, drug resistance and drug-associated toxicity are likely to have a beneficial impact on long-term cost-effectiveness and resource use. In the setting of equivalent virological efficacy, determining the acceptable threshold at which differences in the risk of toxicity, tolerability and convenience outweigh differences in resource use and cost will be important. These thresholds may differ among clinicians and patients alike.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In developing the recommendations in these guidelines, the Writing Group has taken into account differences in critical treatment outcomes between different drug regimens in determining preferred and alternative treatment regimens. The Writing Group recognizes and supports that commissioning arrangements and local drug costs will and should influence ART choice where outcomes, across a range of clinical measures, are equivalent between individual drugs in the treatment of defined patient populations. The Writing Group, however, believes that reducing treatment costs should not be at the cost of an increased risk of poorer treatment outcomes and quality of care, not least as these are likely to have a detrimental impact on long-term cost.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Before final approval by the Writing Group, the guidelines were published online for public consultation and an external peer review was commissioned.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In addition, two meetings with patients and community representatives were held to discuss and receive feedback and comment on the proposed guideline recommendations. The first was held before the Writing Group's consensus meeting and the second as part of the public consultation process.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The quality of evidence (&lt;strong&gt;A&amp;ndash;D&lt;/strong&gt;) and grades of recommendation (&lt;strong&gt;1, 2, good practice point [GPP]&lt;/strong&gt;) are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Patient Involvement in Decision-making&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients are given the opportunity to be involved in making decisions about their treatment (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;Provision of treatment-support resources should include in-house, independent and community information providers and peer-support resources. &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;When to Start&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Chronic Infection&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients with chronic infection start antiretroviral therapy (ART) if the CD4 cell count is &amp;le;350 cells/&amp;micro;L (&lt;strong&gt;1A&lt;/strong&gt;): it is important not to delay treatment initiation if the CD4 cell count is close to this threshold.&#xA;    &lt;p&gt;The absolute risk of disease progression is significantly higher for a given CD4 cell count in older people (see Table 4.1 in the original guideline document), so consideration should be given to starting at higher CD4 cell counts in older persons. Evidence from cohort studies suggest that the risk of disease progression is significantly higher once the CD4 cell count falls below 350 cells/&amp;micro;L. Therefore, it is important not to delay unnecessarily the initiation of ART if the CD4 cell count is close to this threshold.&lt;/p&gt;&#xA;    &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients with the following conditions start ART:&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;        &lt;li&gt;Acquired immune deficiency syndrome (AIDS) diagnosis (e.g., Kaposi sarcoma [KS]) irrespective of CD4 cell count (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xA;        &lt;li&gt;Human immunodeficiency virus (HIV)-related comorbidity, including HIV-associated nephropathy (HIVAN) (&lt;strong&gt;1C&lt;/strong&gt;), idiopathic thrombocytopenic purpura (&lt;strong&gt;1C&lt;/strong&gt;), symptomatic HIV-associated neurocognitive (NC) disorders irrespective of CD4 cell count (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;        &lt;li&gt;Coinfection with hepatitis B virus (HBV) if the CD4 cell count is &amp;le;500 cells/&amp;micro;L (&lt;strong&gt;1B&lt;/strong&gt;) (see &quot;Hepatitis B&quot; below and in Section 8.2.2 in the original guideline document). &lt;/li&gt;&#xA;        &lt;li&gt;Coinfection with hepatitis C virus (&lt;span&gt;HCV&lt;/span&gt;) if the CD4 cell count is &amp;le;500 cells/&amp;micro;L (&lt;strong&gt;1C&lt;/strong&gt;) (see &quot;Hepatitis C&quot; below and in Section 8.2.3 in the original guideline document). &lt;/li&gt;&#xA;        &lt;li&gt;Non-AIDS-defining malignancies (NADMs) requiring immunosuppressive radiotherapy or chemotherapy (&lt;strong&gt;1C&lt;/strong&gt;) (see &quot;When to Start ART: Non-AIDS-defining Malignancies&quot; below and in Section 8.3.2 in the original guideline document). &lt;/li&gt;&#xA;    &lt;/ul&gt;&#xA;    &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group suggests patients with the following conditions start ART:&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;        &lt;li&gt;Coinfection with HBV if the CD4 cell count is &amp;gt;500 cells/&amp;micro;L and treatment of hepatitis B is indicated (&lt;strong&gt;2B&lt;/strong&gt;) (see &quot;Hepatitis B&quot; below and in Section 8.2.2 in the original guideline document). &lt;/li&gt;&#xA;    &lt;/ul&gt;&#xA;    &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Patients Presenting with AIDS or a Major Infection&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients presenting with an AIDS-defining infection, or with a serious bacterial infection and a CD4 cell count &amp;lt;200 cells/&amp;micro;L, start ART within 2 weeks of initiation of specific antimicrobial chemotherapy (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Treatment of Primary HIV Infection&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients presenting with primary HIV infection (PHI) and meeting any 1 of the following criteria start ART:&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;        &lt;li&gt;Neurological involvement (&lt;strong&gt;1D&lt;/strong&gt;) &lt;/li&gt;&#xA;        &lt;li&gt;Any AIDS-defining illness (&lt;strong&gt;1A&lt;/strong&gt;) &lt;/li&gt;&#xA;        &lt;li&gt;Confirmed CD4 cell count &amp;lt;350 cells/&amp;micro;L (&lt;strong&gt;1C&lt;/strong&gt;) &lt;/li&gt;&#xA;    &lt;/ul&gt;&#xA;    &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Treatment to Reduce Transmission&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends the evidence that treatment with ART lowers the risk of transmission is discussed with all patients, and an assessment of the current risk of transmission to others is made at the time of this discussion (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends following discussion, if a patient with a CD4 cell count &amp;gt;350 cells/&amp;micro;L wishes to start ART to reduce the risk of transmission to partners, this decision is respected and ART is started (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;What to Start&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends therapy-na&amp;iuml;ve patients start ART containing two nucleos(t)ide reverse transcriptase inhibitors (NRTI) plus one of the following: a ritonavir-boosted protease inhibitor (PI/r), a non-nucleos(t)ide reverse transcriptase inhibitor (NNRTI) or an integrase inhibitor (INI) (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Table. Summary Recommendations for Choice of ART&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: Summary Recommendations for Choice of ART&quot;&gt;&#xA;    &lt;thead&gt;&#xA;        &lt;tr&gt;&#xA;            &lt;th valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xA;            &lt;th valign=&quot;top&quot;&gt;Preferred&lt;/th&gt;&#xA;            &lt;th valign=&quot;top&quot;&gt;Alternative&lt;/th&gt;&#xA;        &lt;/tr&gt;&#xA;    &lt;/thead&gt;&#xA;    &lt;tbody&gt;&#xA;        &lt;tr&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;Nucleos(t)ide reverse transcriptase inhibitor (NRTI) backbone&lt;/td&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;Tenofovir (TDF) and emtricitabine (FTC)&lt;/td&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;Rilpivirine (RPV)&amp;Dagger;&lt;/td&gt;&#xA;        &lt;/tr&gt;&#xA;        &lt;tr&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;Third agent&lt;/td&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;Atazanavir/ritonavir (ATV/r)&lt;br /&gt;&#xA;            Darunavir/ritonavir (DRV/r)&lt;br /&gt;&#xA;            Efavirenz (EFV)&lt;br /&gt;&#xA;            Raltegravir (RAL)&lt;br /&gt;&#xA;            Elvitegravir (ELV)/cobicistat (COBI)&lt;/td&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;Abacavir (ABC) and lamivudine (3TC)*&amp;Dagger;&lt;br /&gt;&#xA;            Lopinavir/ritonavir (LPV/r)&lt;br /&gt;&#xA;            Fosamprenavir/ritonavir (FPV/r)&lt;br /&gt;&#xA;            Nevirapine (NVP)&amp;dagger;&lt;/td&gt;&#xA;        &lt;/tr&gt;&#xA;    &lt;/tbody&gt;&#xA;&lt;/table&gt;&#xA;&lt;p class=&quot;Note&quot;&gt;*ABC is contraindicated if human leukocyte antigen (HLA)-B*57:01 positive.&lt;/p&gt;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;dagger;NVP is contraindicated if baseline CD4 cell count is &amp;gt;250/400 cells/&amp;micro;L in women/men.&lt;/p&gt;&#xA;&lt;p class=&quot;Note&quot;&gt;&amp;Dagger;Use recommended only if baseline viral load (VL) is &amp;lt;100,000 copies/mL: RPV as a third agent, ABC and 3TC as NRTI backbone.&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The presence or future risk of comorbidities and potential adverse effects need to be considered in the choice of antiretroviral (ARV) drugs in individual patients. &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Which NRTI Backbone&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends therapy-na&amp;iuml;ve patients start combination ART containing tenofovir (TDF) and emtricitabine (FTC) as the NRTI backbone (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group suggests abacavir (ABC) and lamivudine (3TC) is an acceptable alternative NRTI backbone in therapy-na&amp;iuml;ve patients who, before starting ART, have a baseline viral load (VL) of &amp;le;100 000 copies/mL (&lt;strong&gt;2A&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;ABC must not be used in patients who are human leukocyte antigen (HLA)-B*57:01 positive (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Which Third Agent&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends therapy-na&amp;iuml;ve patients start combination ART containing atazanavir/ritonavir (ATV/r), darunavir/ritonavir (DRV/r), efavirenz (EFV),&amp;nbsp;raltegravir (RAL), or elvitegravir (ELV)/cobicistat (COBI) as a third agent (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group suggests that for therapy-na&amp;iuml;ve patients lopinavir/ritonavir (LPV/r) and fosamprenavir/ritonavir (FPV/r) are acceptable alternative protease inhibitor (PIs), and nevirapine (NVP) and&amp;nbsp;rilpivirine (RPV) are acceptable alternative NNRTIs (&lt;strong&gt;2A&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;NVP must only be used according to CD4 criteria and RPV should only be used in patients with baseline VL &amp;lt;100,000 copies/mL. &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Novel ART Strategies&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends against the use of PI monotherapy as initial therapy for treatment-na&amp;iuml;ve patients (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends against the use of PI-based dual ART with a single NRTI, NNRTI, C&amp;ndash;C chemokine receptor type 5 (CCR5) receptor antagonist or INI as an initial therapy for treatment-na&amp;iuml;ve patients (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Supporting Patients on Therapy&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Adherence&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;em&gt;Interventions to Increase Adherence to Treatment&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends adherence and potential barriers to it are assessed and discussed with the patient whenever ART is prescribed or dispensed (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends adherence support should address both perceptual barriers (e.g., beliefs and preferences) and/or practical barriers (e.g., limitations in capacity and resources) to adherence (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;em&gt;Should the Choice of First-line ART Combination Be Affected by Risk of Non-adherence?&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;In patients where there is clinical concern that doses may be missed intermittently, there is insufficient evidence to recommend a PI/r over EFV-based regimens. However, where there is a risk of frequent prolonged treatment interruptions, EFV-based regimens may be associated with more frequent selection for drug resistance compared with PI/r. &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Pharmacology&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;em&gt;Drug Interactions&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends that potential adverse pharmacokinetic interactions between ARV drugs and other concomitant medications are checked before administration (with tools such as &lt;a href=&quot;http://www.hiv-druginteractions.org&quot; title=&quot;HIV Drug Interactions Web site&quot;&gt;http://www.hiv-druginteractions.org&lt;/a&gt;) (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;em&gt;Therapeutic Drug Monitoring&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends against the unselected use of therapeutic drug monitoring (TDM) (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;TDM may be of clinical value in specific populations (e.g., children, pregnant women) or selected clinical scenarios (e.g., malabsorption, drug interactions, suspected non-adherence to therapy). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;em&gt;Stopping Therapy: Pharmacological Considerations&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients stopping ART containing an NNRTI in combination with an NRTI backbone replace all drugs with a PI (LPV/r) for 4 weeks (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients stopping a PI-containing regimen stop all drugs simultaneously and no replacement is required (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;em&gt;Switching Therapy: Pharmacological Considerations&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Data on how to switch away from EFV to an alternative 'third' agent are either non-existent, or of low or very low quality. Based on pharmacological principles, there is little rationale for any strategy other than straightforward substitution when switching to a PI/r or RAL. Pharmacokinetic studies show that straightforward substitution with etravirine (ETV) and RPV may result in slightly lower concentrations of either drug for a short period following switching, but limited virological data suggest that risk of virological failure with this strategy is low. Different strategies for switching to NVP have been proposed, but no comparative data are available to guide the choice of strategy. Limited data suggest that the dose of MVC should be doubled in the week following switching (unless given together with a PI/r). &lt;/li&gt;&#xA;    &lt;li&gt;If switching away from EFV is undertaken when VL is likely to still to be detectable (e.g., because of central nervous system [CNS] intolerance within the first few weeks of starting EFV), substitution with a PI/r in preference to a within-class switch is advised. &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Switching ART in Virological Suppression&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;em&gt;Switching Antiretrovirals in Combination ART&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends, in patients on suppressive ART regimens, consideration is given to differences in side effect profile, drug&amp;ndash;drug interactions (DDI) and drug resistance patterns before switching any ARV component (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends in patients with previous NRTI resistance mutations, against switching a PI/r to either an NNRTI or an INI as the third agent (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;em&gt;PI Monotherapy&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends continuing standard combination ART as the maintenance strategy in virologically suppressed patients (&lt;strong&gt;1C&lt;/strong&gt;). (There are insufficient data to recommend PI/r monotherapy in this clinical situation.) &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Stopping Therapy&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends against treatment interruption or intermittent therapy in patients stable on a virally suppressive ART regimen (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Managing Virological Failure&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Blips, Low-level Viraemia and Virological Failure&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;In patients on ART:&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;        &lt;li&gt;A single VL 50&amp;ndash;400 copies/mL preceded and followed by an undetectable VL is usually not a cause for clinical concern (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;        &lt;li&gt;The Writing Group recommends a single VL &amp;gt;400 copies/mL is investigated further, as it is indicative of virological failure (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;        &lt;li&gt;The Writing Group recommends, in the context of repeated viral blips, resistance testing is attempted (&lt;strong&gt;1D&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;/ul&gt;&#xA;    &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Patients with No or Limited Drug Resistance&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients experiencing virological failure on first-line ART with wild-type (WT) virus at baseline and without emergent resistance mutations at failure switch to a PI/r-based combination ART regimen (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients experiencing virological failure on first-line ART with WT virus at baseline and limited emergent resistance mutations (including two-class NRTI/NNRTI) at failure switch to a new PI/r-based regimen with the addition of at least one, preferably two, active drugs (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients experiencing virological failure on first-line PI/r plus two-NRTI-based regimens, with major protease mutations, switch to a new active PI/r with the addition of at least one, preferably two, active agents of which one has a novel mechanism of action (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends against switching a PI/r to an INI or NNRTI as the third agent in patients with historical or existing reverse transcriptase (RT) mutations associated with NRTI resistance or past virological failure on NRTIs (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Patients with Triple-class (NNRTI, NRTI, PI) Virological Failure with or without Triple-class Resistance&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients with persistent viraemia and with limited options to construct a fully suppressive regimen are discussed/referred for expert advice (or through virtual clinic referral) (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients with triple-class resistance switch to a new ART regimen containing at least two and preferably three fully active agents with at least one active PI/r such as DRV/r or tipranavir/ritonavir (TPV/r) and one agent with a novel mechanism (CCR5 receptor antagonist or integrase/fusion inhibitor) with ETV an option based on viral susceptibility (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Patients with Limited or No Therapeutic Options When a Fully Viral Suppressive Regimen Cannot Be Constructed&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends accessing newer agents through research trials, expanded access and named patient programmes (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group suggests continuing/commencing NRTIs as this may contribute partial ARV activity to a regimen, despite drug resistance (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends the use of 3TC or FTC to maintain a mutation at codon position 184 of the RT gene (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends against discontinuing or interrupting ART (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends against adding a single, fully active ARV because of the risk of further resistance (&lt;strong&gt;1D&lt;/strong&gt;) &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends against the use of maraviroc (MVC) to increase the CD4 cell count in the absence of CCR5 tropic virus. (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Antiretroviral Therapy in Specific Populations&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;HIV with Tuberculosis Coinfection&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;em&gt;When to Start Antiretroviral Therapy&lt;/em&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Table. Timing of Initiation of ART during Tuberculosis (TB) Therapy&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;1&quot; summary=&quot;Table: Timing of Initiation of ART during Tuberculosis (TB) Therapy&quot;&gt;&#xA;    &lt;thead&gt;&#xA;        &lt;tr&gt;&#xA;            &lt;th valign=&quot;top&quot;&gt;CD4 Cell Count (cells/&amp;micro;L)&lt;/th&gt;&#xA;            &lt;th valign=&quot;top&quot;&gt;When to Start Highly Active Antiretroviral Therapy (HAART)&lt;/th&gt;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Grade&lt;/th&gt;&#xA;        &lt;/tr&gt;&#xA;    &lt;/thead&gt;&#xA;    &lt;tbody&gt;&#xA;        &lt;tr&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;lt;100&lt;/td&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;As soon as practical within 2 weeks after starting TB therapy&lt;/td&gt;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1B&lt;/th&gt;&#xA;        &lt;/tr&gt;&#xA;        &lt;tr&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;100&amp;ndash;350&lt;/td&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;As soon as practical, but can wait until after completing 2 months' TB treatment, especially when there are difficulties with drug interactions, adherence and toxicities&lt;/td&gt;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1B&lt;/th&gt;&#xA;        &lt;/tr&gt;&#xA;        &lt;tr&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;gt;350&lt;/td&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;At physician's discretion&lt;/td&gt;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;1B&lt;/th&gt;&#xA;        &lt;/tr&gt;&#xA;    &lt;/tbody&gt;&#xA;&lt;/table&gt;&#xA;&lt;p&gt;&lt;em&gt;What to Start&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends EFV in combination with TDF and FTC as first-line ART in TB/HIV coinfection (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends that when rifampicin is used with EFV in patients over 60 kg, the EFV dose is increased to 800 mg daily. Standard doses of EFV are recommended if the patient weighs &amp;lt;60 kg (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends that rifampicin is not used with either NVP or a PI/r (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends that where effective ART necessitates the use of PI/r, that rifabutin is used instead of rifampicin (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;HIV and Viral Hepatitis Coinfection&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Table. Summary of When to Start Recommendations&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;1&quot; summary=&quot;Table: Summary of When to Start Recommendations&quot;&gt;&#xA;    &lt;thead&gt;&#xA;        &lt;tr&gt;&#xA;            &lt;th valign=&quot;top&quot;&gt;CD4 Cell Count (cells/&amp;micro;L)&lt;/th&gt;&#xA;            &lt;th valign=&quot;top&quot;&gt;Hepatitis B Virus (HBV) Requiring Treatment*&lt;/th&gt;&#xA;            &lt;th valign=&quot;top&quot;&gt;HBV Not Requiring Treatment&lt;/th&gt;&#xA;            &lt;th valign=&quot;top&quot;&gt;Hepatitis C Virus (HCV) with Immediate Plan to Start HCV Treatment*&lt;/th&gt;&#xA;            &lt;th valign=&quot;top&quot;&gt;HCV with No Immediate Plan to Start HCV Treatment&lt;/th&gt;&#xA;        &lt;/tr&gt;&#xA;    &lt;/thead&gt;&#xA;    &lt;tbody&gt;&#xA;        &lt;tr&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;gt;500&lt;/td&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;Start antiretroviral therapy (ART) (&lt;strong&gt;1C&lt;/strong&gt;)&lt;br /&gt;&#xA;            (Include tenofovir [TDF] and emtricitabine [FTC])&lt;/td&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consider ART (&lt;strong&gt;2C&lt;/strong&gt;)&lt;br /&gt;&#xA;            (Include TDF and FTC)&lt;/td&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consider ART before HCV treatment commenced (&lt;strong&gt;2C&lt;/strong&gt;)&lt;/td&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consider ART (&lt;strong&gt;2D&lt;/strong&gt;)&lt;/td&gt;&#xA;        &lt;/tr&gt;&#xA;        &lt;tr&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;le;500&lt;/td&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;Start ART (&lt;strong&gt;1B&lt;/strong&gt;) (Include TDF and FTC)&lt;/td&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;Start ART (&lt;strong&gt;1B&lt;/strong&gt;) (Include TDF and FTC)&lt;/td&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;Start ART before HCV treatment commenced (&lt;strong&gt;1C&lt;/strong&gt;)&lt;br /&gt;&#xA;            Discuss with HIV and viral hepatitis specialist&lt;/td&gt;&#xA;            &lt;td valign=&quot;top&quot;&gt;Start ART (&lt;strong&gt;1C&lt;/strong&gt;)&lt;/td&gt;&#xA;        &lt;/tr&gt;&#xA;    &lt;/tbody&gt;&#xA;&lt;/table&gt;&#xA;&lt;p class=&quot;Note&quot;&gt;*See the National Guideline Clearinghouse summary &lt;a href=&quot;/content.aspx?id=47758&quot; title=&quot; Guideline #10199&quot;&gt;British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013&lt;/a&gt; for indications to treat hepatitis B and C.&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Hepatitis B&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;em&gt;When to Start ART&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients with HIV and HBV coinfection who have a CD4 cell count &amp;lt;500 cells/&amp;micro;L are treated with fully suppressive ART inclusive of anti-HBV active antivirals (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients with HIV and HBV coinfection who have a CD4 cell count &amp;ge;500 cells/&amp;micro;L and who have an HBV-deoxyribonucleic acid (DNA) &amp;ge;2000 IU/mL and/or evidence of more than minimal fibrosis (Metavir &amp;ge;F2) are treated with fully suppressive ART inclusive of anti-HBV active antivirals (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;em&gt;What to Start&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends TDF/FTC as part of a fully suppressive ART combination should be given to all patients where HBV treatment is deemed necessary (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends neither 3TC nor FTC be used as the sole active drug against HBV in ART due to the rapid emergence of HBV resistant to these agents (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends 3TC/FTC may be omitted from the ART regimen and tenofovir be given as the sole anti-HBV active agent if there is clinical or genotypic evidence of 3TC/FTC-resistant HBV or HIV (&lt;strong&gt;1D&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Hepatitis C&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;em&gt;When to Start ART&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends all patients with HIV and HCV coinfection be assessed for HCV treatment (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group suggests commencing ART when the CD4 cell count is &amp;gt;500 cells/&amp;micro;L in all patients who are not to commence HCV treatment immediately (&lt;strong&gt;2D&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends commencing ART when the CD4 cell count is &amp;lt;500 cells/&amp;micro;L in all patients who are not to commence anti-HCV treatment immediately (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends commencing ART to optimize immune status before anti-HCV therapy is initiated when the CD4 cell count is between 350 and 500 cells/&amp;micro;L unless there is an urgent indication for anti-HCV treatment when ART should be commenced as soon as the patient has been stabilized on HCV therapy (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends commencing ART to allow immune recovery before anti-HCV therapy is initiated when the CD4 cell count is &amp;lt;350 cells/&amp;micro;L (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;em&gt;What to Start&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends if patients are commencing ART, and direct-acting antivirals (DAAs) are not being considered, standard first-line ART should be commenced (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends when DAAs are to be used there is careful consideration of possible DDIs (&lt;strong&gt;1C&lt;/strong&gt;) and current or archived HIV resistance. All drug interactions should be checked with an expert source (e.g., &lt;a href=&quot;http://www.hiv-druginteractions.org&quot; title=&quot;HIV Drug Interactions Web site&quot;&gt;www.hiv-druginteractions.org&lt;/a&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends if boceprevir is to be used, RAL with TDF plus FTC should be the treatment of choice for those with WT HIV (&lt;strong&gt;1C&lt;/strong&gt;): pharmacokinetic data would support ETV, RPV and MVC as alternatives. &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends if telaprevir is to be used either RAL or standard-dose ATV/r should be used (&lt;strong&gt;1C&lt;/strong&gt;): pharmacokinetic data would support ETV, RPV and MVC as alternatives. EFV may be used but the telaprevir dose needs to be increased to 1125 mg three times a day (tds). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group suggests that if ABC is to be used with ribavirin, the ribavirin should be weight-based dose-adjusted (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;HIV-related Cancers&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;em&gt;When to Start ART: AIDS-defining Malignancies&lt;/em&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Kaposi Sarcoma&lt;/span&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends starting ART in HIV-positive patients with KS (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Non-Hodgkin Lymphoma (NHL)&lt;/span&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends starting ART in HIV-positive patients with NHL (&lt;strong&gt;1B&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Cervical Cancer&lt;/span&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group suggests starting ART in HIV-positive patients with cervical cancer (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends starting ART in HIV-positive patients who are commencing radiotherapy or chemotherapy for cervical cancer (&lt;strong&gt;1D&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;em&gt;When to Start ART: NADM&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group suggests starting ART in HIV-positive patients with NADM (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends starting ART in HIV-positive patients who are commencing immunosuppressive radiotherapy or chemotherapy for NADM (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;em&gt;What to Start&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends that potential pharmacokinetic interactions between ARVs and systemic anticancer therapy are checked before administration (with tools such as: &lt;a href=&quot;http://www.hiv-druginteractions.org&quot; title=&quot;HIV Drug Interactions Web site&quot;&gt;http://www.hiv-druginteractions.org&lt;/a&gt;) (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group suggests avoiding ritonavir-boosted ART in HIV-positive patients who are to receive cytotoxic chemotherapy agents that are metabolized by the cytochrome P450 (CYP450) enzyme system (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends against the use of ATV in HIV-positive patients who are to receive irinotecan (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group suggests avoiding ARV agents in HIV-positive patients who are to receive cytotoxic chemotherapy agents that have overlapping toxicities (&lt;strong&gt;2C&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;HIV-Associated NC Impairment&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;em&gt;When to Start ART&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients with symptomatic HIV-associated NC disorders start ART irrespective of CD4 lymphocyte count (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;em&gt;What to Start&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients with HIV-associated NC disorders start standard combination ART regimens (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;em&gt;Modification of ART&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;In patients with ongoing or worsening NC impairment despite ART, the Writing Group recommends the following best practice management (&lt;strong&gt;GPP&lt;/strong&gt;):&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;        &lt;li&gt;Reassessment for confounding conditions &lt;/li&gt;&#xA;        &lt;li&gt;Assessment of cerebrospinal fluid (CSF) HIV ribonucleic acid (RNA), CSF HIV genotropism and genotyping of CSF HIV RNA &lt;/li&gt;&#xA;        &lt;li&gt;In subjects with detectable CSF HIV RNA, modifications to ART should be based on plasma and CSF genotypic and genotropism results. &lt;/li&gt;&#xA;    &lt;/ul&gt;&#xA;    &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Chronic Kidney Disease&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;em&gt;When to Start ART&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients with HIVAN start ART immediately irrespective of CD4 cell count (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends patients with end-stage kidney disease who are suitable candidates for renal transplantation start ART irrespective of CD4 cell count (&lt;strong&gt;1C&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;em&gt;What to Start&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends against the use of ARV drugs that are potentially nephrotoxic, in patients with stages 3&amp;ndash;5 chronic kidney disease (CKD) if acceptable alternative ARV agents are available (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends dose adjustment of renally cleared ARV drugs in patients with reduced renal function (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Cardiovascular Disease&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;em&gt;What to Start&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group suggests avoiding: ABC (&lt;strong&gt;2C&lt;/strong&gt;), FPV/r (&lt;strong&gt;2C&lt;/strong&gt;) and LPV/r (&lt;strong&gt;2C&lt;/strong&gt;) in patients with a high cardiovascular disease (CVD) risk, if acceptable alternative ARV drugs are available. &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Women&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;em&gt;When to Start&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends therapy-na&amp;iuml;ve HIV-positive women who are not pregnant start ART according to the same indicators as in men (see &quot;When to Start&quot; above and in Section 4 in the original guideline document) (&lt;strong&gt;1A&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;em&gt;What to Start&lt;/em&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;The Writing Group recommends therapy-na&amp;iuml;ve HIV-positive women start ART containing two NRTIs and one of the following: PI/r, NNRTI or INI (&lt;strong&gt;1A&lt;/strong&gt;), as per therapy-na&amp;iuml;ve HIV-positive men. &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends therapy-na&amp;iuml;ve HIV-positive women start ART with preferred or alternative NRTI backbone and third agent as per therapy-na&amp;iuml;ve HIV-positive men (&lt;strong&gt;1A&lt;/strong&gt;) (See &quot;What to Start: Summary Recommendations&quot; above and in section 5.1 in the original guideline document) &lt;/li&gt;&#xA;    &lt;li&gt;Factors such as potential side effects, comorbidities, drug interactions, patient preference and dosing convenience need to be considered in selecting ART in individual women. &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends both HIV-positive women of childbearing potential and healthcare professionals who prescribe ART are conversant with the benefits and risks of ARV agents for both the health of HIV-positive women and for that of an unborn child (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;    &lt;li&gt;The Writing Group recommends that potential pharmacokinetic interactions between ARVs, hormonal contraceptive agents and hormone replacement therapy are checked before administration (with tools such as: &lt;a href=&quot;http://www.hiv-druginteractions.org&quot; title=&quot;HIV Drug Interactions Web site&quot;&gt;http://www.hiv-druginteractions.org&lt;/a&gt;) (&lt;strong&gt;GPP&lt;/strong&gt;). &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Quality of Evidence&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Grade A evidence&lt;/strong&gt; means high-quality evidence that comes from consistent results from well- performed randomised controlled trials (RCTs), or overwhelming evidence from another source (such as well-executed observational studies with consistent strong effects and exclusion of all potential sources of bias). Grade A implies confidence that the true effect lies close to the estimate of the effect.&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Grade B evidence&lt;/strong&gt; means moderate-quality evidence from randomised trials that suffers from serious flaws in conduct, inconsistency, indirectness, imprecise estimates, reporting bias, or some combination of these limitations, or from other study designs with specific strengths such as observational studies with consistent effects and exclusion of the majority of the potential sources of bias.&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Grade C evidence&lt;/strong&gt; is low-quality evidence from controlled trials with several serious limitations, or observational studies with limited evidence on effects and exclusion of most potential sources of bias.&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Grade D evidence&lt;/strong&gt; is based only on case studies, expert judgement or observational studies with inconsistent effects and a potential for substantial bias, such that there can be little confidence in the effect estimate.&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Summary of the Modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) System&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;1A&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Strong recommendation. &lt;/li&gt;&#xA;    &lt;li&gt;High-quality evidence. &lt;/li&gt;&#xA;    &lt;li&gt;Benefits clearly outweigh risk and burdens, or vice versa. &lt;/li&gt;&#xA;    &lt;li&gt;Consistent evidence from well performed randomised, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change confidence in the estimate of benefit and risk. &lt;/li&gt;&#xA;    &lt;li&gt;Strong recommendations can apply to most patients in most circumstances without reservation. &lt;/li&gt;&#xA;    &lt;li&gt;Clinicians should follow a strong recommendation unless there is a clear rationale for an alternative approach. &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;1B&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Strong recommendation. &lt;/li&gt;&#xA;    &lt;li&gt;Moderate-quality evidence. &lt;/li&gt;&#xA;    &lt;li&gt;Benefits clearly outweigh risk and burdens, or vice versa &lt;/li&gt;&#xA;    &lt;li&gt;Evidence from randomised, controlled trials with important limitations (inconsistent results, methods flaws, indirect or imprecise), or very strong evidence of some other research design. Further research may impact on confidence in the estimate of benefit and risk. &lt;/li&gt;&#xA;    &lt;li&gt;Strong recommendation and applies to most patients. &lt;/li&gt;&#xA;    &lt;li&gt;Clinicians should follow a strong recommendation unless a clear and compelling rationale for an alternative approach is present. &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;1C&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Strong recommendation. &lt;/li&gt;&#xA;    &lt;li&gt;Low-quality evidence. &lt;/li&gt;&#xA;    &lt;li&gt;Benefits appear to outweigh risk and burdens, or vice versa &lt;/li&gt;&#xA;    &lt;li&gt;Evidence from observational studies, unsystematic clinical experience, or from randomised, controlled trials with serious flaws. Any estimate of effect is uncertain. &lt;/li&gt;&#xA;    &lt;li&gt;Strong recommendation, and applies to most patients. Some of the evidence base supporting the recommendation is, however, of low quality. &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;1D&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Strong recommendation. &lt;/li&gt;&#xA;    &lt;li&gt;Very low-quality evidence. &lt;/li&gt;&#xA;    &lt;li&gt;Benefits appear to outweigh risk and burdens, or vice versa. &lt;/li&gt;&#xA;    &lt;li&gt;Evidence limited to case studies. Strong recommendation based mainly on case studies and expert judgment. &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;2A&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Weak recommendation. &lt;/li&gt;&#xA;    &lt;li&gt;High-quality evidence. &lt;/li&gt;&#xA;    &lt;li&gt;Benefits closely balanced with risks and burdens &lt;/li&gt;&#xA;    &lt;li&gt;Consistent evidence from well performed randomised, controlled trials or overwhelming evidence of some other form. Further research is unlikely to change confidence in the estimate of benefit and risk. &lt;/li&gt;&#xA;    &lt;li&gt;Weak recommendation, best action may differ depending on circumstances or patients' or societal values. &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;2B&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Weak recommendation. &lt;/li&gt;&#xA;    &lt;li&gt;Moderate-quality evidence. &lt;/li&gt;&#xA;    &lt;li&gt;Benefits closely balanced with risks and burdens, some uncertainty in the estimates of benefits, risks and burdens. &lt;/li&gt;&#xA;    &lt;li&gt;Evidence from randomised, controlled trials with important limitations (inconsistent results, methods flaws, indirect or imprecise). Further research may change the estimate of benefit and risk. &lt;/li&gt;&#xA;    &lt;li&gt;Weak recommendation, alternative approaches likely to be better for some patients under some circumstances. &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;2C&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Weak recommendation. &lt;/li&gt;&#xA;    &lt;li&gt;Low-quality evidence. &lt;/li&gt;&#xA;    &lt;li&gt;Uncertainty in the estimates of benefits, risks, and burdens; benefits may be closely balanced with risks and burdens. &lt;/li&gt;&#xA;    &lt;li&gt;Evidence from observational studies, unsystematic clinical experience, or from randomised, controlled trials with serious flaws. Any estimate of effect is uncertain. &lt;/li&gt;&#xA;    &lt;li&gt;Weak recommendation; other alternatives may be reasonable. &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;2D&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Weak recommendation. &lt;/li&gt;&#xA;    &lt;li&gt;Very low-quality evidence. &lt;/li&gt;&#xA;    &lt;li&gt;Uncertainty in the estimates of benefits, risks, and burdens; benefits may be closely balanced with risks and burdens. &lt;/li&gt;&#xA;    &lt;li&gt;Evidence limited to case studies and expert judgment. &lt;/li&gt;&#xA;    &lt;li&gt;Very weak recommendation; other alternatives may be equally reasonable. &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Good Practice Points (GPP)&lt;/strong&gt; are recommendations based on the clinical judgment and experience of the working group. GPPs emphasise an area of important clinical practice for which there is not, nor is there likely to be, any significant research evidence. They address an aspect of treatment and care that is regarded as such sound clinical practice that health care professionals are unlikely to question it and where the alternative recommendation is deemed unacceptable. It must be emphasised that GPPs are not an alternative to evidence-based recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is identified and graded for each recommendation (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Appropriate treatment and management of adults with human immunodeficiency virus (HIV) infection with antiretroviral therapy (ART) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Decreasing the risk of virological failure, drug resistance and drug-associated toxicity are likely to have a beneficial impact on long-term cost-effectiveness and resource use. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Risk of adverse effects of antiretroviral therapy (ART), drug interactions between antiretroviral drugs and concomitant medication, and the development of antiretroviral drug resistance &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The overall event rate is often the same for both men and women, but the adverse event profile may be different. Women were reported to be more likely than men to experience ART-related lipodystrophy, rash and nausea, and to discontinue therapy. Data from the USA have shown that women are more likely than men to discontinue ART for poor adherence, dermatological symptoms, neurological reasons, constitutional symptoms and concurrent medical conditions. Refer to section 8.7.3.2 in the original guideline document for additional discussion of gender differences in toxicity and adherence as well as issues related to fetal safety and potential fetal toxicity of ART. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;See the tables in Appendix 3 in the original guideline document (see the &quot;Availability of Companion Documents&quot; field) for adverse events reported in studies reviewed for this guideline. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;Abacavir is contraindicated in patients who are human leukocyte antigen (HLA)-B*57:01 positive. &lt;/li&gt;&#xA;    &lt;li&gt;Nevirapine is contraindicated if baseline CD4 cell count is &amp;gt;250/400 cells/mL in women/men. &lt;/li&gt;&#xA;    &lt;li&gt;There is no place for the use of stavudine- or didanosine-containing regimens as initial therapy in antiretroviral therapy (ART)-na&amp;iuml;ve patients, due to the associations with significant mitochondrial and hepatic toxicities. &lt;/li&gt;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Dissemination and Implementation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The following measures have/will be undertaken to disseminate and aid implementation of the guidelines:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;E-publication on the British HIV Association (BHIVA) website and the journal &lt;em&gt;HIV Medicine&lt;/em&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Publication in &lt;em&gt;HIV Medicine&lt;/em&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Shortened version detailing concise summary of recommendations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;E-learning module accredited for continuing medical education (CME) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Educational slide set to support local and regional educational meetings &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;National BHIVA audit programme &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Audit Criteria/Indicators" /><FieldValue Value="Mobile Device Resources" /><FieldValue Value="Patient Resources" /><FieldValue Value="Slide Presentation" /><FieldValue Value="Staff Training/Competency Material" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /><FieldValue Value="Staying Healthy" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Writing Group, Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S, Fidler S, Fisher M, Freedman A, Geretti AM, Gilleece Y, Horne R, Johnson M, Khoo S, Leen C, Marshall N, Nelson M, Orkin C, Paton N, Phillips A, Post F, Pozniak A, Sabin C, Trevelion R, Ustianowski A, Walsh J, Waters L, Wilkins E, Winston A, Youle M. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 2014 Jan;15(Suppl 1):1-85. [564 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24330011&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2008 (revised 2014 Jan)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="British HIV Association - Disease Specific Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;British HIV Association&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Writing Group&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Writing Group Members&lt;/em&gt;: Dr Ian Williams (&lt;em&gt;Chair&lt;/em&gt;), Senior Lecturer, University College London and Honorary Consultant Physician, Central and North West London NHS Foundation Trust; Dr Duncan Churchill (&lt;em&gt;Vice-chair&lt;/em&gt;), Consultant Physician in HIV and Genitourinary Medicine, Brighton and Sussex University Hospitals NHS Trust; Prof Jane Anderson, Consultant Physician and Director of the Centre for the Study of Sexual Health and HIV, Homerton University Hospital NHS Foundation Trust, London; Dr Marta Boffito, Consultant Physician in HIV Medicine, Chelsea and Westminster Hospital NHS Foundation Trust, London; Prof Mark Bower, Professor of Oncology, Imperial College London and Consultant Physician in Medical Oncology, Chelsea and Westminster Hospital NHS Foundation Trust, London; Mr Gus Cairns, UK Community Advisory Board representative/HIV treatment advocates network; Dr Kate Cwynarski, Consultant Physician in Haematology, Royal Free London NHS Foundation Trust; Dr Simon Edwards (&lt;em&gt;Section Lead&lt;/em&gt;), Consultant Physician in HIV and Genitourinary Medicine, Central and North West London NHS Foundation Trust; Dr Sarah Fidler, Senior Lecturer in HIV and Genitourinary Medicine, Imperial College School of Medicine at St Mary's, London; Dr Martin Fisher (&lt;em&gt;Section Lead&lt;/em&gt;), Consultant Physician in HIV and Genitourinary Medicine, Brighton and Sussex University Hospitals NHS Trust; Dr Andrew Freedman, Reader in Infectious Diseases and Honorary Consultant Physician, Cardiff University School of Medicine; Prof Anna Maria Geretti, Professor of Virology and Infectious Diseases, Institute of Infection and Global Health, University of Liverpool; Dr Yvonne Gilleece, Consultant Physician in HIV and Genitourinary Medicine, Brighton and Sussex University Hospitals NHS Trust; Prof Rob Horne, Professor of Behavioural Medicine, Head of Department of Practice and Policy and Director of Centre for Behavioural Medicine, University College London; Prof Margaret Johnson, Professor in HIV Medicine and Clinical Director of HIV/AIDS Services, Royal Free London NHS Foundation Trust; Prof Saye Khoo, Honorary Consultant Physician in Infectious Diseases and Professor of Translational Medicine, University of Liverpool; Prof Clifford Leen, Consultant Physician in Infectious Diseases, Western General Hospital, Edinburgh and Honorary Professor in Infectious Diseases, Edinburgh University; Mr Neal Marshall, Specialist HIV Pharmacist, Royal Free London NHS Foundation Trust; Dr Mark Nelson, Consultant Physician, Chelsea and Westminster Hospital NHS Foundation Trust, London; Dr Chloe Orkin, Consultant Physician and Lead for HIV Research, Barts Health NHS Trust, London; Dr Nicholas Paton, Senior Clinical Scientist, Medical Research Council Clinical Trials Unit, London; Prof Andrew Phillips, Professor of Epidemiology, University College London; Dr Frank Post, Senior Lecturer, King's College London and Honorary Consultant Physician in Infectious Diseases, King's College Hospital NHS Foundation Trust, London; Dr Anton Pozniak, Consultant Physician, Chelsea and Westminster Hospital NHS Foundation Trust and Honorary Senior Lecturer, Imperial College London; Prof Caroline Sabin, Professor of Medical Statistics and Epidemiology, University College London; Mr Roy Trevelion, UK Community Advisory Board representative/HIV treatment advocates network; Dr Andrew Ustianowski, Consultant in Infectious Diseases and Tropical Medicine and Associate Clinical Director, North Manchester General Hospital; Dr John Walsh, Consultant Physician in HIV and Sexual Health, Imperial College Healthcare NHS Trust, London; Dr Laura Waters, Consultant Physician in HIV and Genitourinary Medicine, Central and North West London NHS Foundation Trust; Dr Edmund Wilkins (&lt;em&gt;Section Lead&lt;/em&gt;), Consultant Physician in Infectious Diseases and Director of the HIV Research Unit, North Manchester General Hospital; Dr Alan Winston, Consultant Physician, Imperial College Healthcare NHS Trust and Senior Lecturer in HIV and Genitourinary Medicine, Imperial College London; Dr Mike Youle, Director of HIV Clinical Research, Royal Free London NHS Foundation Trust&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Conflicts of Interest Statements&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Ian Williams has received grant support from Gilead Sciences and Janssen-Cilag and his department has received grant support from Boehringer Ingelheim, Gilead Sciences and Janssen-Cilag.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Duncan Churchill has no conflicts of interest to declare.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Professor Jane Anderson has received lecture fees from Abbott, Gilead and ViiV and consultancy fees from Abbott, Bristol-Myers Squibb and Gilead. Her department has received a research grant from Gilead.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Professor Jose Arribas has a financial interest/relationship or affiliation: Tibotec, Janssen, Abbott, BMS, Gilead Sciences, MSD, ViiV Healthcare.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Marta Boffito has received consultancy fees and grant support from Bristol-Myers Squibb, GlaxoSmithKline, Merck Sharp and Dohme, Pfizer, Roche and Tibotec/Janssen.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Professor Mark Bower has no conflicts of interest to declare.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Mr Gus Cairns has no conflicts of interest to declare.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Kate Cwynarski has received lecture and consultancy fees from Pfizer and Roche.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Annemiek de Ruiter has received lecture and consultancy fees from Bristol-Myers Squibb and Gilead.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Simon Edwards has received lecture fees from ViiV and Janssen, and consultancy fees from Boehringer Ingelheim, Merck Sharp and Dohme and ViiV.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr S Fidler has no conflicts of interest to declare.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Martin Fisher has received lecture fees from Abbott, Astellis, Bristol-Myers Squibb, Gilead and ViiV and he has received consultancy fees from Abbott, Bristol-Myers Squibb, Gilead, Janssen, Merck Sharp and Dohme and ViiV.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Andrew Freedman has received lecture and consultancy fees from Abbott, Bristol-Myers Squibb, Gilead and Tibotec/Janssen.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Professor Anna Maria Geretti has received consultancy fees from Gilead and her department has received research grants from Janssen, Merck Sharp and Dohme and ViiV.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Yvonne Gilleece has no conflicts of interest to declare.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Professor Rob Horne has no conflicts of interest to declare.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Professor Margaret Johnson has received lecture and consultancy fees from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Janssen and Merck Sharp and Dohme.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Professor Saye Khoo has received lecture and consultancy fees from Abbott, Gilead and ViiV.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Professor Clifford Leen has received consultancy fees from AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Janssen and Merck Sharp and Dohme. His department has received research awards from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Janssen and ViiV.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Fiona Lyons has no conflicts of interest to declare.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Mr Neal Marshall has received lecture and consultancy fees from Abbott, Bristol-Myers Squibb, Janssen and ViiV.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Mark Nelson has received lecture fees from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Merck Sharp and Dohme, Tibotec and ViiV and consultancy fees from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Idenix, Merck Sharp and Dohme, Pfizer, Tibotec, and ViiV. His department has received research grants from Abbott, Aspen Pharmaceuticals, Bristol-Myers Squibb, Gilead, Merck Sharp and Dohme, Tibotec and ViiV.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Chloe Orkin has received lecture fees from Abbott, Boehringer-Ingelheim, Bristol-Myers Squibb, Gilead, GSK, Janssen, Merck Sharp and Dohme, Pfizer, Tibotec and ViiV. She has received consultancy fees from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GSK, Janssen, Merck Sharp and Dohme, Pfizer, Tibotec and ViiV. Her department has received research grants from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GSK, Janssen, Merck Sharp and Dohme, Pfizer, Tibotec and ViiV.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Nicholas Paton's department has received research grants from Abbott and Merck Sharp and Dohme.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Professor Andrew Phillips has received consultancy fees from Bristol-Myers Squibb, Gilead, GSK Bio, Johnson and Johnson, Merck Sharp and Dohme and ViiV and his department has received research grants from Bristol-Myers Squibb.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Frank Post has received lecture fees from Bristol-Myers Squibb, Gilead, Merck Sharp and Dohme, Tibotec/Janssen and ViiV/GSK and his department has received research grants from Gilead and ViiV.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Anton Pozniak has received lecture and consultancy fees from Boehringer Ingelheim and Bristol-Myers Squibb, Gilead, Janssen, Merck Sharp and Dohme and ViiV and conference support from Bristol-Myers Squibb and Merck Sharp and Dohme.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Professor Raffi has received research funding or honoraria from or consulted for Abbott, Avexa, Boehringer-Ingelheim, Bristol-Myers Squibb, Ferrer, Gilead, Janssen, Merck Sharp and Dohme, Pfizer, Roche, Schering-Plough, ViiV Healthcare.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Professor Caroline Sabin has received lecture and consultancy fees from Abbott, Bristol-Myers Squibb, Gilead, and Janssen.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Mr Roy Trevelion has no conflict of interests to declare.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Andy Ustianowski has received lecture and consultancy fees from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Merck Sharp and Dohme, Janssen and ViiV and his department has received research grants from Abbott.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Laura Waters has received lecture and consultancy fees from Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, Janssen, Merck Sharp and Dohme and ViiV.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr John Walsh has no conflict of interests to declare.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Ed Wilkins has received lecture and consultancy fees from Abbott, Bristol-Myers Squibb, Gilead, Janssen, Merck Sharp and Dohme and Pfizer.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Alan Winston has received lecture fees from Janssen and his department has received research grants from Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, Gilead, GlaxoSmithKline, Janssen, Pfizer, Roche and ViiV.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr Mike Youle has received lecture and consultancy fees from Abbott and Gilead.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Gazzard B, on behalf of the BHIVA Treatment Guidelines Writing Group. British HIV Association guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med 2008;9:563&amp;ndash;608.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;http://www.bhiva.org/TreatmentofHIV1_2012.aspx&quot; title=&quot;British HIV Association (BHIVA) Web site&quot;&gt;British HIV Association (BHIVA) Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following are available:&lt;/p&gt;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xA;    &lt;li&gt;British HIV Association guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012. Appendices. London (UK): British HIV Association (BHIVA); 2013 Nov. Electronic copies: Available from the &lt;a href=&quot;http://www.bhiva.org/TreatmentofHIV1_2012.aspx&quot; title=&quot;British HIV Association (BHIVA) Web site&quot;&gt;British HIV Association (BHIVA) Web site&lt;/a&gt;. &lt;/li&gt;&#xA;    &lt;li&gt;British HIV Association guidelines for the treatment of HIV-1 positive adults with antiretroviral therapy 2012. Slide presentation. London (UK): British HIV Association (BHIVA); 2013 Nov. 96 p. Available in &lt;a href=&quot;http://www.bhiva.org/documents/Guidelines/Treatment/2012/140211SlideSet.pptx&quot; title=&quot;British HIV Association (BHIVA) Web site&quot;&gt;PowerPoint&lt;/a&gt; and &lt;a href=&quot;http://www.bhiva.org/documents/Guidelines/Treatment/2012/140211SlideSet.pdf&quot; title=&quot;British HIV Association (BHIVA) Web site&quot;&gt;PDF&lt;/a&gt; from the BHIVA Web site. &lt;/li&gt;&#xA;    &lt;li&gt;Treatment of HIV-1 positive adults with antiretroviral therapy (E-Learning Module 4). Available to members from the &lt;a href=&quot;http://www.bhiva.org/E-LearningModule4.aspx&quot; title=&quot;British HIV Association (BHIVA) Web site&quot;&gt;BHIVA Web site&lt;/a&gt;. &lt;/li&gt;&#xA;    &lt;li&gt;British HIV Association (BHIVA) guideline development manual. London (UK): British HIV Association (BHIVA); 2014 Jan 28. 44 p. Electronic copies: Available from the &lt;a href=&quot;http://www.bhiva.org/documents/Guidelines/DevtManual/GuidelineDevelopmentManual.pdf&quot; title=&quot;British HIV Association (BHIVA) Web site&quot;&gt;BHIVA Web site&lt;/a&gt;. &lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;Auditable outcomes are available in Section 2.2 of the &lt;a href=&quot;http://www.bhiva.org/documents/Guidelines/Treatment/2012/hiv1029_2.pdf&quot; title=&quot;British HIV Association (BHIVA) Web site&quot;&gt;original guideline document&lt;/a&gt;.&lt;/p&gt;&#xA;&lt;p&gt;Smartphone apps are available from the &lt;a href=&quot;http://www.bhiva.org/Apps.aspx&quot; title=&quot;British HIV Association (BHIVA) Web site&quot;&gt;BHIVA Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A patient-friendly version of this British HIV Association (BHIVA) guideline is available from the &lt;a href=&quot;http://www.bhiva.org/HIV-treatment-for-adults-2013.aspx&quot; title=&quot;BHIVA Web site&quot;&gt;BHIVA Web site&lt;/a&gt;.&lt;/p&gt;&#xA;&lt;p class=&quot;Disclaimer&quot;&gt;Please note: This patient information is intended to provide health professionals with information to share with their patients to help them better understand their health and their diagnosed disorders. By providing access to this patient information, it is not the intention of NGC to provide specific medical advice for particular patients. Rather we urge patients and their representatives to review this material and then to consult with a licensed health professional for evaluation of treatment options suitable for them as well as for diagnosis and answers to their personal medical questions. This patient information has been derived and prepared from a guideline for health care professionals included on NGC by the authors or publishers of that original guideline. The patient information is not reviewed by NGC to establish whether or not it accurately reflects the original guideline's content.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on May 9, 2014.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
